Billiontoone (NASDAQ:BLLN) SVP Bosch John Roderick Ten Sells 1,416 Shares of Stock

Key Points

• Insider sale: BillionToOne SVP Bosch John Roderick Ten sold 1,416 shares for $169,920 at an average price of $120.00, reducing his direct holdings by 5.99% to 22,219 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Stock performance and fundamentals: BLLN traded at $121.72, with a $5.74 billion market capitalization and a 52-week range of $61.96 to $150.44. The company reported quarterly revenue of $109.45 million and EPS of $0.15, in line with analyst expectations.
• Analyst outlook: BillionToOne has a consensus rating of Hold and an average price target of $125.88, with seven Buy, two Hold, and two Sell ratings among analysts tracked by MarketBeat.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) SVP Bosch John Roderick Ten sold 1,416 shares of the firm's stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $120.00, for a total value of $169,920.00. Following the completion of the sale, the senior vice president directly owned 22,219 shares of the company's stock, valued at approximately $2,666,280. This represents a 5.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, September 21st, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $106.61, for a total value of $150,959.76.
• On Wednesday, September 9th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $97.54, for a total transaction of $138,116.64.
• On Tuesday, August 25th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total transaction of $141,700.00.
• On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total transaction of $131,582.62.

Billiontoone Stock Performance

NASDAQ:BLLN traded down $1.36 during trading hours on Monday, hitting $121.72. 343,637 shares of the company were exchanged, compared to its average volume of 551,483. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $150.44. The stock has a market capitalization of $5.74 billion and a price-to-earnings ratio of 173.89. The company's 50 day moving average price is $108.73 and its 200-day moving average price is $98.51.

Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million during the quarter. As a group, research analysts forecast that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Billiontoone in the 2nd quarter valued at about $29,000. MCF Advisors LLC boosted its stake in shares of Billiontoone by 330.8% in the second quarter. MCF Advisors LLC now owns 448 shares of the company's stock worth $54,000 after buying an additional 344 shares during the last quarter. Thrive Wealth Management LLC acquired a new stake in Billiontoone during the second quarter worth about $240,000. Caitong International Asset Management Co. Ltd acquired a new stake in Billiontoone during the fourth quarter worth about $230,000. Finally, Jasper Ridge Partners L.P. purchased a new position in Billiontoone during the second quarter valued at approximately $615,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Guggenheim initiated coverage on Billiontoone in a research note on Monday, June 29th. They set a "buy" rating and a $125.00 price target on the stock. BTIG Research reduced their price objective on Billiontoone from $142.00 to $130.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Canaccord Genuity Group assumed coverage on Billiontoone in a report on Wednesday, September 2nd. They set a "buy" rating and a $120.00 target price for the company. Weiss Ratings reiterated a "sell (d+)" rating on shares of Billiontoone in a research report on Friday, September 18th. Finally, Wall Street Zen lowered shares of Billiontoone from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $125.88.

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company's technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company's primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.